Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥8,000 JPY
Change Today -32.00 / -0.40%
Volume 1.2M
4523 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
Frankfurt
As of 2:00 AM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (4523) Snapshot

Open
¥8,000
Previous Close
¥8,032
Day High
¥8,054
Day Low
¥7,947
52 Week High
03/24/15 - ¥9,756
52 Week Low
05/13/14 - ¥3,900
Market Cap
2.4T
Average Volume 10 Days
1.5M
EPS TTM
¥140.71
Shares Outstanding
296.6M
EX-Date
03/27/15
P/E TM
56.9x
Dividend
¥150.00
Dividend Yield
1.88%
Current Stock Chart for EISAI CO LTD (4523)

Related News

No related news articles were found.

eisai co ltd (4523) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (4523) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome, as well as consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; BELVIQ, an antiobesity agent; Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment; Lyrica, a treatment for postherpetic neuralgia; and Lunesta, a treatment for insomnia. Additionally, the company is involved in the research and development of various products under the areas of oncology, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has strategic partnerships with Quintiles Inc.; SFJ Pharma Ltd.; Biogen Idec, Inc.; BioArctic Neuroscience AB; FORMA Therapeutics, Inc.; Epizyme, Inc.; PRISM BioLab Co., Ltd.; and Verastem, Inc. for the discovery and development of various products. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,419 Employees
Last Reported Date: 06/20/14
Founded in 1941

eisai co ltd (4523) Top Compensated Officers

Chief Executive Officer, Representative Corpo...
Total Annual Compensation: ¥115.0M
Chief Clinical Officer of Eisai Product Creat...
Total Annual Compensation: ¥84.0M
Compensation as of Fiscal Year 2014.

eisai co ltd (4523) Key Developments

Eisai and Nihon Medi-Physics Sign Agreement on Diagnosis and Treatment of Dementia in Japan

Eisai (Japan) has signed a collaboration agreement with Nihon Medi-Physics (Japan) on the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan, the companies said in a statement. Under the agreement, the companies will share information on dementia including DLB, and generate new evidence to improve the diagnosis and treatment of DLB. The partnership is expected to leverage Eisai's knowledge and experience of drug discovery for dementia, reflected in its development of Aricept (donepezil hydrochloride), which targets the suppression of progression of dementia symptoms in DLB. DLB is one of Japan's three main types of dementia as well as Alzheimer's disease and vascular dementia and affects up to 41.4% of the country's elderly patients with dementia.

153 Workers of Eisai Could Lose Jobs in June 2015

Eisai announced that up to 153 workers who work at or report to Eisai's U.S. headquarters in Woodcliff Lake could lose their jobs in June 2015. The company reported in a notice to the state Department of Labor that laid-off workers would include regional business directors, medical sales specialists and district managers. The employees are losing their jobs as part of a companywide restructuring, affecting workers at locations throughout the country. The company expects to decide by May 1, 2015, with layoffs coming in June 2015.

Eisai Co., Ltd.and Genomics plc to Collaborate in Analyses of Largescale Genotype/Phenotype Data to Inform Drug Development

Eisai Co., Ltd. and Genomics plc announced that they have entered into a collaborative agreement to use Genomics's sophisticated statistical analyses of large-scale multi-phenotype genetic association data to inform Eisai's drug discovery process, including target selection, target validation, indication selection and repositioning. Both companies believe that human genetics and genomics can add great value to the drug development process. Genomics, the Oxford based genome analytics company, will be partnering with Eisai's new Integrated Human Genomics (IHGx) Research Unit which operates directly under the supervision of Eisai Product Creation Systems' Chief Clinical Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4523:JP ¥8,000.00 JPY -32.00

4523 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €16.63 EUR -0.03
Ironwood Pharmaceuticals Inc $13.87 USD +0.38
Nektar Therapeutics $11.41 USD +0.24
Shire PLC 5,205 GBp 0.00
Synergy Health PLC 2,225 GBp -5.00
View Industry Companies
 

Industry Analysis

4523

Industry Average

Valuation 4523 Industry Range
Price/Earnings 56.8x
Price/Sales 4.1x
Price/Book 3.9x
Price/Cash Flow 59.0x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit www.eisai.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.